Opinion of the Transparency Council – cyclophosphamide
At its meeting on 10 February 2025, the Transparency Council adopted opinion No. 28/2025 on the reimbursement of medicines containing the active substance cyclophosphamide for indications, dosages or methods of administration other than those specified in the Summary of Product Characteristics, i.e. haemophagocytic syndrome; POEMS syndrome; thrombocytopenia refractory to corticosteroid treatment; hemolytic anemia refractory to corticosteroid treatment